EGFR-Mutated NSCLC: Role of Value-Based Frameworks in Treatment Evaluation

In this segment, Dr. Sands asks Dr. Wakelee to discuss the role of value-based frameworks in evaluating first-line treatment options for EGFR-mutated non-small cell lung cancer. Dr. Wakelee explains that tools such as the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale can provide structured approaches to interpreting clinical trial data, particularly when comparing efficacy and safety across treatment options. However, she notes that in clinical practice, these frameworks are not always routinely applied at the individual patient level. Instead, clinicians often rely on a combination of clinical judgment, detailed understanding of trial data, and patient-specific factors. The discussion highlights that while value frameworks can be informative at a population level or for guideline development, treatment decisions in EGFR-mutated NSCLC remain highly individualized. Overall, this segment underscores that these frameworks are helpful as reference tools but are not a substitute for nuanced, patient-centered clinical decision-making.